GENENTA SCIENCE S.P.A. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.59 USD | -11.12% |
|
-33.61% | -47.68% |
| 04-08 | Genenta Science S.P.A. Announces Resignation of Board Members | CI |
| 03-29 | Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 174.7 | 93.62 | 81.7 | 44.2 | - | - |
| Enterprise Value (EV) 1 | 174.7 | 93.62 | 81.7 | 44.2 | 44.2 | 44.2 |
| P/E ratio | -26.1 x | -10.9 x | -7.01 x | -3.32 x | -3.07 x | -3.11 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | -8,481,777 x | - | - | - | - |
| EV / FCF | -25,074,510 x | - | - | - | - | - |
| FCF Yield | -0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 18,120 | 18,217 | 18,217 | 18,217 | - | - |
| Reference price 2 | 9.641 | 5.139 | 4.485 | 2.426 | 2.426 | 2.426 |
| Announcement Date | 02/05/22 | 21/04/23 | 29/03/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | -11.04 | - | - | - | - |
| EBIT 1 | - | -5.687 | -11.04 | -11.73 | -15.11 | -18.36 | -22.04 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -5.529 | -8.478 | -11.65 | -15.11 | -18.36 | -22.04 |
| Net income 1 | -5.592 | -5.529 | -8.478 | -11.65 | -15.11 | -18.36 | -22.04 |
| Net margin | - | - | - | - | - | - | - |
| EPS 2 | -0.3800 | -0.3700 | -0.4700 | -0.6400 | -0.7300 | -0.7900 | -0.7800 |
| Free Cash Flow | - | -6.967 | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 09/11/21 | 02/05/22 | 21/04/23 | 29/03/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 S2 | 2022 Q2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - |
| EBITDA | - | - | - | -4.151 | -6.887 | -6.779 | - |
| EBIT | - | -1.646 | - | - | -6.89 | - | -4.933 |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | -1.481 | - | -2.112 | -6.365 | -6.759 | -4.886 |
| Net income | -4.048 | -1.481 | - | -2.112 | -6.365 | -6.759 | -4.886 |
| Net margin | - | - | - | - | - | - | - |
| EPS | -0.2700 | -0.1000 | - | -0.1200 | -0.3500 | -0.3700 | -0.2700 |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 24/11/21 | 02/05/22 | 25/10/22 | 25/10/22 | 21/04/23 | 20/10/23 | 29/03/24 |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | -6.97 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - |
| Announcement Date | 09/11/21 | 02/05/22 | 21/04/23 | 29/03/24 | - | - | - |
1EUR in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.426
EUR
Average target price
21.37
EUR
Spread / Average Target
+780.73%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -47.68% | 47.18M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- GNTA Stock
- Financials Genenta Science S.p.A.
